For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.

It's probably too late to put the champagne back in the bottle.

Some six months after biotech giant Illumina gained regulatory approval for its $7 billion acquisition of cancer-screening company Grail, the Federal Trade Commission is stepping in to overturn the decision and putting the kibosh on the entire deal.

Continue reading

Source Fool.com